TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00494429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Gestational Age\< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Gestational Age\>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
Study: NCT02044562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nitrate supplementation
Description: A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
Study: NCT02448745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insecticide treated wall lining
Description: Polypropylene non-woven fabric.
Study: NCT01995344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study: NCT02627443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03040973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Tablet for oral use; 150 mg, 200 mg; twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Tablet for oral use; 150 mg, 200 mg; twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Tablet for oral use; 150 mg, 200 mg; twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Tablet for oral use; 150 mg, 200 mg; twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nazartinib
Description: Capsule for oral use; 25 mg, 50 mg; once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: tablets for oral use; 250mg; once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Tablets for oral use; 40 mg, 80 mg; once a day.
Study: NCT03793478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Administered orally once daily starting on Day 6 and continuing through Day 28;~Optional low intensity consolidation with chemotherapy:~Administered orally once daily starting on Day 1 and continuing through Day 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day IV infusion given over 30 minutes on Days 1 through 5 (administered based on body weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m\^2/day IV infusion given over 3 hours on Days 1 through 5 (begin 4 hours after the start of fludarabine) (administered in accordance with standard of care);~Optional high intensity consolidation with chemotherapy and quizartinib:~500 mg/m\^2/day as a continuous 96-hour IV infusion on Days 1 through 4;~Optional low intensity consolidation with chemotherapy:~75 mg/m\^2/day as once daily subcutaneous or IV on Days 1 through 4 and Days 15 through 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) triple chemotherapy prophylaxis
Description: IT cytarabine, methotrexate, and either prednisolone or hydrocortisone; doses are based on the participant's age and standard practice at each site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Optional high intensity consolidation with chemotherapy and quizartinib:~100 mg/m\^2/dose once daily as an IV infusion over 3 hours on Days 1 through 5
Study: NCT06068075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FoundationOne Liquid CDx
Description: a FoundationOne liquid biopsy test kit will be sent to the laboratory of the subject's treating center, in addition to the paired cell stabilizing tube from the primary center
Study: NCT03394365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
Study: NCT04507555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing
Description: The study intervention is the service of pharmacist guided pre-emptive PGx testing to support clinical decision making for antidepressant selection and dosing.~This service involves genotyping and thereof evidence-based genotype interpretation commercially offered as Stratipharm® (humatrix AG, Pfungstadt Germany, https://www.stratipharm.de). Furthermore, clinical pharmacists will process and evaluate the results from PGx testing (Stratipharm®) in context of the individual patient medication history as well as current co-medication and forward an individualized recommendation for antidepressant selection and dosing to the treating psychiatrist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care antidepressant selection and dosing
Description: Selection and dosing of the new antidepressant pharmacotherapy will be determined by the treating investigator alone, according to current standard of care considering clinical factors only.
Study: NCT04471961

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Exome sequencing in pediatrics cancers
Description: This pediatric oncology study proposing a global approach integrating trio-based whole exome sequencing, somatic DNA and RNA analysis will improve the recognition of genetic predisposition and the characterization of target therapies in children with cancer.
Study: NCT04396236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00861705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT04396574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study: NCT01995344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tumour Infiltrating Lymphocytes

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Tumour Infiltrating Lymphocytes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Study: NCT03026829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART sound therapy
Description: The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART
Study: NCT00078845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 500 mg three times a week.
Study: NCT03426943

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arterial blood sampling
Description: All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arterial blood sampling
Description: All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ultrafiltrate sampling
Description: All patients will have ultrafiltrate sampling to assess cytokine levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrafiltrate sampling
Description: All patients will have ultrafiltrate sampling to assess cytokine levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVVH using oXiris™ filter
Description: Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH using PrismafleX HF1400 filter
Description: Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
Study: NCT04873635

Intervention type: OTHER
Intervention: Implant support prostheses
Description: Implant support prostheses was provided to restore the missing teeth and tissues removed due to pathological jaw lesions
Study: NCT00996034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [123I]5-IA-85380
Description: up to 10 mCi of \[123I\]5-IA-85380, I.V. on each of two SPECT Scan days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine bitartrate
Description: 0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
Study: NCT00647595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
Study: NCT01602497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: Patients will undergo ten session of sham rTMS.
Study: NCT03833232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omentopexy with cyanoacrilate glue
Description: apposition of omentum with cyanoacrilate glue on gastric section
Study: NCT03910881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-platform patient support system (PSS) app
Description: The PSS app enables tracking and visualization of patient-selected health outcomes and sharing of select outcomes with family and providers. The CF clinical team and the family jointly decide which aspects of daily life to track, how often, and the content and frequency of patient-generated reports. Examples of daily care that can be tracked include symptoms (respiratory, gastrointestinal, pain), energy level, appetite, sleep, exercise, mood, medications, therapies, school/work attendance. Prior to a clinic visit, the patient/family generates a report of the outcomes they have been tracking, to help prepare for the visit and identify successes and areas of struggle. This information facilitates meaningful conversations during the visit and promotes shared decision-making. Patients/families can view their progress at any time and share selected outcomes with family and friends as often as desired.
Study: NCT03683563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4% sodium citrate
Description: the catheter will be locked with 4% citrate solution after each dialysis session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% sodium citrate
Description: the catheter will be locked with 30% citrate solution after each dialysis session
Study: NCT01502033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: 30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
Study: NCT02018432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast escalation dosage
Description: This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast conventional dosage
Description: Roflumilast 500 μg once daily for 12 weeks
Study: NCT01124799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo dose in the morning, at noon and in the evening, for 9 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
Study: NCT04003376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional carbon dioxide laser alone
Description: six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser alone
Description: six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser alone
Description: six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser alone
Description: six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 10mg/mL
Description: six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D solution
Description: six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
Study: NCT02935296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention
Description: systems navigation, psychosocial counseling
Study: NCT01158937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Infusion
Description: Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem Infusion
Description: Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
Study: NCT01592123

Intervention type: PROCEDURE
Intervention: The active anterior rhinomanometry
Description: In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.

Intervention type: BEHAVIORAL
Intervention: The Pittsburgh Sleep Quality Index (PSQI)
Description: PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score \>5 is considered to be suggestive of significant sleep disturbance.

Intervention type: BEHAVIORAL
Intervention: The Beck Anxiety Inventory (BAI)
Description: The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.

Intervention type: BEHAVIORAL
Intervention: The Van Dream Anxiety Scale (VDAS)
Description: The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
Study: NCT00791037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Undergo leukapheresis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded HER2-specific T cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given ID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT02999841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: 1-2 week: 50mg tid; 3-24 week: 100mg tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: 1-24 week: 50mg bid
Study: NCT02264210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
Study: NCT03956030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contraception Handout
Description: Handout covering contraception options

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Handout
Description: Handout covering nutrition
Study: NCT02298088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180 mg
Description: Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg.
Study: NCT02890563

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class II Compression Stockings